Stock Market Reviews

Read and share opinions on DTIL (Precision BioSciences, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mar

Latest News

• Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants
  Nov 10, 2025
• Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts
  Nov 10, 2025
• Precision BioSciences: Q3 Earnings Snapshot
  Nov 3, 2025
• Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update
  Nov 3, 2025
• Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025
  Oct 31, 2025
• Precision BioSciences (DTIL) Moves 11.1% Higher: Will This Strength Last?
  Oct 16, 2025
• Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025
  Oct 14, 2025
• Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases
  Oct 9, 2025
• Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial
  Oct 7, 2025
• Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society
  Sep 30, 2025
• Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium
  Sep 12, 2025
• Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status
  Sep 8, 2025
• Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates
  Aug 7, 2025
• Precision BioSciences: Q2 Earnings Snapshot
  Aug 7, 2025
• Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update
  Aug 7, 2025
• Precision BioSciences Says PBGENE-HBV Showed 'Substantial' Antiviral Activity in Hepatitis B Patients
  Aug 6, 2025
• Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B
  Aug 6, 2025